SHP099 suppresses RAS-ERK signaling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models, highlighting the fact that SHP-2 can be pharmacologically inhibited and opening the door to small-drug inhibition in clinics. This evidence concerns the gene NTRK1 and cancer.